Epigenetic mechanisms in cancer

被引:13
作者
Banerjee, Hirendra Nath [1 ]
Verma, Mukesh [2 ]
机构
[1] Elizabeth City State Univ, Dept Biol, Elizabeth City, NC 27909 USA
[2] NCI, Methods & Technol Branch, Epidemiol & Genet Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA
关键词
acetylation; cancer; chromatin; epigenetics; histone; methylation; miRNA; RDA; representational differential analysis; tumor; CELL LUNG-CANCER; TUMOR-SUPPRESSOR GENE; ACUTE MYELOID-LEUKEMIA; MGMT PROMOTER HYPERMETHYLATION; CPG ISLAND HYPERMETHYLATION; DNA METHYLATION MARKERS; GROWTH-FACTOR-II; COLORECTAL-CANCER; BREAST-CANCER; COLON-CANCER;
D O I
10.2217/BMM.09.26
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
After the completion of the human genome, a need was identified by scientists to look for a functional map of the human genome. Epigenomics provided functional characteristics of genes identified in the genome. Epigenetics is the alteration in gene expression (function) without changing the nucleotide sequence. Both activation and inactivation of cancer-associated genes can occur by epigenetic mechanisms. The major players in epigenetic mechanisms of gene regulation are DNA methylation, histone deacetylation, chromatin remodeling, small noncoding RNA expression and gene imprinting. In the last few years, epigenetic mechanisms have been studied in a number of tumor types and epigenetic markers have been identified that are suitable for cancer detection, diagnosis, follow-up of treatment and screening high-risk populations. One interesting aspect of epigenetics is the reactivation of genes by successful reversion of some epigenetic changes using chemicals. The reversibility of epigenetic aberrations has made them attractive targets for cancer treatment with modulators that demethylate DNA and inhibit histone deacetylases, leading to the reactivation of silenced genes. In this article, we have described the current status of this powerful science and discussed the challenges in the clinical fields where epigenetic approaches in cancer are applied.
引用
收藏
页码:397 / 410
页数:14
相关论文
共 215 条
[11]   Global histone modifications predict prognosis of resected non-small-cell lung cancer [J].
Barlesi, Fabrice ;
Giaccone, Giuseppe ;
Gallegos-Ruiz, Marielle I. ;
Loundou, Anderson ;
Span, Simone W. ;
Lefesvre, Pierre ;
Kruyt, Frank A. E. ;
Rodriguez, Jose Antonio .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) :4358-4364
[12]   High-resolution profiling of histone methylations in the human genome [J].
Barski, Artern ;
Cuddapah, Suresh ;
Cui, Kairong ;
Roh, Tae-Young ;
Schones, Dustin E. ;
Wang, Zhibin ;
Wei, Gang ;
Chepelev, Iouri ;
Zhao, Keji .
CELL, 2007, 129 (04) :823-837
[13]   Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort [J].
Belinsky, SA ;
Liechty, KC ;
Gentry, FD ;
Wolf, HJ ;
Rogers, J ;
Vu, K ;
Haney, J ;
Kenned, TC ;
Hirsch, FR ;
Miller, Y ;
Franklin, WA ;
Herman, JG ;
Baylin, SB ;
Bunn, PA ;
Byers, T .
CANCER RESEARCH, 2006, 66 (06) :3338-3344
[14]  
Berjapibal Mongkol, 2007, Journal of the Medical Association of Thailand, V90, P1986
[15]   Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk [J].
Berndt, Sonja I. ;
Potter, John D. ;
Hazra, Aditi ;
Yeager, Meredith ;
Thomas, Gilles ;
Makar, Karen W. ;
Welch, Robert ;
Cross, Amanda J. ;
Huang, Wen-Yi ;
Schoen, Robert E. ;
Giovannucci, Edward ;
Chan, Andrew T. ;
Chanock, Stephen J. ;
Peters, Ulrike ;
Hunter, David J. ;
Hayes, Richard B. .
HUMAN MOLECULAR GENETICS, 2008, 17 (17) :2665-2672
[16]   Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents [J].
Bishton, Mark ;
Kenealy, Melita ;
Johnstone, Ricky ;
Rasheed, Walid ;
Prince, H. Miles .
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (10) :1439-1449
[17]   Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors [J].
Bjornsson, Hans T. ;
Brown, Lindsey J. ;
Fallin, M. Danielle ;
Rongione, Michael A. ;
Bibikova, Marina ;
Wickham, Eliza ;
Fan, Jian-Bing ;
Feinberg, Andrew P. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (16) :1270-1273
[18]   Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression [J].
Bueno, Maria J. ;
Perez de Castro, Ignacio ;
de Cedron, Marta Gomez ;
Santos, Javier ;
Calin, George A. ;
Cigudosa, Juan C. ;
Croce, Carlo M. ;
Fernandez-Piqueras, Jose ;
Malumbres, Marcos .
CANCER CELL, 2008, 13 (06) :496-506
[19]   Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer [J].
Calmon, Marilia F. ;
Colombo, Jucimara ;
Carvalho, Fabricio ;
Souza, Fatima P. ;
Filho, Jose F. G. ;
Fukuyama, Erica E. ;
Camargo, Anamaria A. ;
Caballero, Otavia L. S. ;
Tajara, Eloiza H. ;
Cordeiro, Jose A. ;
Rahal, Paula .
CANCER GENETICS AND CYTOGENETICS, 2007, 173 (01) :31-37
[20]   Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour [J].
Cerrato, Flavia ;
Sparago, Angela ;
Verde, Gaetano ;
De Crescenzo, Agostina ;
Citro, Valentina ;
Cubellis, Maria Vittoria ;
Rinaldi, Maria Michela ;
Boccuto, Luigi ;
Neri, Giovanni ;
Magnani, Cinzia ;
D'Angelo, Paolo ;
Collini, Paola ;
Perotti, Daniela ;
Sebastio, Gianfranco ;
Maher, Eamonn R. ;
Riccio, Andrea .
HUMAN MOLECULAR GENETICS, 2008, 17 (10) :1427-1435